Cargando…

Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis

Although no evidence of disease activity (NEDA) permits evaluation of response to treatment in the systematic follow-up of patients with multiple sclerosis (MS), its ability to accomplish detection of surreptitious activity of disease is limited, thus being unable to prevent patients from falling in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Londoño, Ana C., Mora, Carlos A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000Research 2017
Materias:	Opinion Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446020/ https://www.ncbi.nlm.nih.gov/pubmed/28588765 http://dx.doi.org/10.12688/f1000research.11349.2

Ejemplares similares

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis
por: Rotstein, Dalia, et al.
Publicado: (2022)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
por: Amato, Maria Pia, et al.
Publicado: (2023)

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]
por: Newsome, Scott D., et al.
Publicado: (2023)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
por: Simonsen, Cecilia Smith, et al.
Publicado: (2022)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

NEDA—NEutron Detector Array
por: Valiente-Dobón, J J, et al.
Publicado: (2019)

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Genomics: what is realistically achievable?
por: Overbeek, Ross
Publicado: (2000)

Citicoline: A Candidate for Adjunct Treatment of Multiple Sclerosis
por: Grieb, Paweł, et al.
Publicado: (2021)

Clinical predictors of NEDA-3 one year after diagnosis of pediatric multiple sclerosis: an exploratory single-center study
por: Palavra, Filipe, et al.
Publicado: (2023)

VEP Score of a Left Eye Had Predictive Values for Achieving NEDA-3 over Ten Years in Patients with Multiple Sclerosis
por: Miletic-Drakulic, Svetlana, et al.
Publicado: (2022)

Stigma Over COVID-19; New Conception Beyond Individual Sense
por: Badrfam, Rahim, et al.
Publicado: (2020)

The New Neutron Multiplicity Filter NEDA and Its First Physics Campaign with AGATA
por: Jaworski, G, et al.
Publicado: (2019)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008)

Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis
por: Dubchenko, Ekaterina, et al.
Publicado: (2020)

Nonconventional MRI biomarkers for in vivo monitoring of pathogenesis in multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2014)

Continued dysregulation of the B cell lineage promotes multiple sclerosis activity despite disease modifying therapies
por: Londoño, Ana C., et al.
Publicado: (2023)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort
por: Jaklin, Andreas K., et al.
Publicado: (2021)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Role of CXCL13 in the formation of the meningeal tertiary lymphoid organ in multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2018)

The importance of collecting structured clinical information on multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?
por: Melnikov, Mikhail, et al.
Publicado: (2021)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up
por: Londoño, Ana C., et al.
Publicado: (2016)

COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination
por: Boziki, Marina Kleopatra, et al.
Publicado: (2020)

Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond
por: Nowicki, Michał, et al.
Publicado: (2021)

Simple Rapid Near-Patient Diagnostics for Tuberculosis Remain Elusive—Is a “Treat-to-Test” Strategy More Realistic?
por: den Hertog, Alice L., et al.
Publicado: (2011)

HIV, malaria and beyond: reducing the disease burden of female adolescents
por: Brabin, Loretta, et al.
Publicado: (2005)

Buprenorphine: Far Beyond the “Ceiling”
por: Infantino, Rosmara, et al.
Publicado: (2021)

Assessing Muscle Fatigue in Multiple Sclerosis using the Sample Entropy of Electromyographic Signals: A Proof of Concept
por: Gomez-Hernández, Marina, et al.
Publicado: (2023)

A Preliminary Study on the Meaning of Inflammatory Indexes in MS: A Neda-Based Approach
por: Bunul, Sena Destan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_doqliu0f08k11uti7qt9orh9rj